What the research found

Researchers tracked vertebral bone strength and density over 12 months in Japanese postmenopausal women using biomechanical CT scanning—a more detailed measure than standard bone density scans. Among treatment-naive patients, romosozumab (Romo) produced roughly a 40% increase in vertebral bone strength, while teriparatide (TPTD) achieved about 24%, and denosumab (DMAb) around 11%.

The sequencing analysis revealed an asymmetry: women who switched from teriparatide to romosozumab saw further gains in bone strength (16% improvement), but the reverse pattern—switching from romosozumab to teriparatide—resulted in loss of the previously built strength despite continued treatment. This suggests the two agents may work through different mechanisms, and the order of deployment matters.

Why it matters for you

If you're tracking bone health as part of metabolic or longevity optimization, this work suggests anabolic bone agents (those that build bone actively, not just slow loss) are not interchangeable. Romosozumab appears to produce the most substantial structural gains in the spine within a year, which may be relevant if you're using it alongside strength training or managing fracture risk.

The sequencing finding is more nuanced: it implies that switching therapies isn't a neutral choice. If you or your clinician are considering rotating anabolic treatments, the direction of rotation may influence outcomes. This is particularly relevant if you're protocol-stacking multiple interventions and tracking biomarkers like bone-specific alkaline phosphatase or P1NP to infer bone turnover.

The study focused on postmenopausal women, so direct application to other populations (men on TRT, younger individuals) remains unclear.

Caveats

• Small sample sizes per arm (16–57 participants), limiting statistical power
• Limited to postmenopausal Japanese women; generalization to other populations unknown
• Single timepoint (12 months); longer-term durability and safety not addressed
• Observational design; no randomization or placebo control
• Biomechanical CT is research-grade; clinical outcomes (fracture reduction) not measured
• Early-stage comparative work; requires validation in larger cohorts